• Organizations: Oculis
FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis
Pipeline

FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis

The neuroprotective candidate is currently being studied in the global PIONEER clinical program for both acute ON and NAION.
Oculis advances neuro-ophthalmic asset after positive FDA feedback
Pipeline

Oculis advances neuro-ophthalmic asset after positive FDA feedback

Privosegtor (OCS-05) gets the green light to be studied in registrational trials beginning this quarter for acute optic neuritis and NAION in 2026.
Phase 3 enrollment concludes for Oculis' DME eye drop program
Pipeline

Phase 3 enrollment concludes for Oculis' DME eye drop program

Topline data readout expected Q2 2026 as lead candidate OCS-01 has the potential to become the first noninvasive eye drop indicated to treat this retinal disease.
Oculis reports positive phase 2b topline data on licaminlimab for DED
Pipeline

Oculis reports positive phase 2b topline data on licaminlimab for DED

OSC-02 eye drop demonstrates rapid treatment effect on corneal inflammation as early as 2 weeks of treatment.
Oculis releases positive phase 3 data from OPTIMIZE-1 trial for post-op inflammation and pain
Pipeline

Oculis releases positive phase 3 data from OPTIMIZE-1 trial for post-op inflammation and pain

Announced at ASCRS, favorable results on once-daily, topical, and preservative-free topical formulation may support an eventual NDA submission.
First patient dosed in Oculis' phase 3 trial of OCS-01 for DME
Pipeline

First patient dosed in Oculis' phase 3 trial of OCS-01 for DME

Stage 2 of the DIAMOND study follows positive results from the first stage, reported in May 2023.
Oculis launches phase 3 OPTIMIZE trial for post-cataract inflammation and pain
Pipeline

Oculis launches phase 3 OPTIMIZE trial for post-cataract inflammation and pain

Study follows positive topline data previously reported from the OPTIMIZE-1 trial in August 2023.
Oculis initiates phase 2b RELIEF trial on OCS-02 for DED
Pipeline

Oculis initiates phase 2b RELIEF trial on OCS-02 for DED

Investigators evaluate a dual mechanism of action single-chain antibody fragment for treating ocular diseases.
LEOPARD trial of OCS-01 eye drops for CME enrolls first patient
Pipeline

LEOPARD trial of OCS-01 eye drops for CME enrolls first patient

Formulation may provide a paradigm shift in the treatment of post-surgical and uveitic macular edema.
Oculis reports positive topline data for phase 3 trial of OCS-01 eye drops
Pipeline

Oculis reports positive topline data for phase 3 trial of OCS-01 eye drops

Formulation could become the first once-daily, topical, preservative-free for inflammation and pain post-cataract surgery.
Positive topline data reported in phase 3 DME trial of OCS-01
Pipeline

Positive topline data reported in phase 3 DME trial of OCS-01

Oculis’s stage 1 of the DIAMOND study supports potential for OCS-01 to become the first topical eye drop and noninvasive DME treatment.
Oculis completes enrollment for post-cataract surgery phase 3 trial
Pipeline

Oculis completes enrollment for post-cataract surgery phase 3 trial

Study is evaluating the use of OCS-01 for treating inflammation and pain following cataract surgery.
Oculis completes patient recruitment for stage 1 of phase 3 DIAMOND study for OCS-01 in DME
Research

Oculis completes patient recruitment for stage 1 of phase 3 DIAMOND study for OCS-01 in DME

OCS-10 is a novel and noninvasive topical therapy for DME.
Can we treat uveitis without steroids? — Weekly Glance
Archives

Can we treat uveitis without steroids? — Weekly Glance

New phase 2 data may have the answer.
Oculis reports positive phase 2 data of OCS-02 for acute anterior uveitis
Pipeline

Oculis reports positive phase 2 data of OCS-02 for acute anterior uveitis

If approved, OCS-02 could become the first topical anti-TNFα for non-infectious anterior uveitis.